

Si-Yang Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11364628/publications.pdf>

Version: 2024-02-01

29
papers

1,448
citations

394421

19
h-index

501196

28
g-index

34
all docs

34
docs citations

34
times ranked

1359
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | GSK2556286 Is a Novel Antitubercular Drug Candidate Effective <i>In Vivo</i> with the Potential To Shorten Tuberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, . | 3.2 | 12 |
| 2 | Differential <i>In Vitro</i> Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, . | 3.2 | 11 |
| 3 | Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant <i>Rv0678</i> Mutant in a Mouse Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0141221. | 3.2 | 16 |
| 4 | Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis. <i>Journal of Infectious Diseases</i> , 2021, 223, 1855-1864. | 4.0 | 15 |
| 5 | Mutations in <i>fbtD</i> (<i>Rv2983</i>) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, . | 3.2 | 48 |
| 6 | Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 3.2 | 62 |
| 7 | Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 3.2 | 9 |
| 8 | High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 3.2 | 15 |
| 9 | Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 3.2 | 35 |
| 10 | Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 3.2 | 37 |
| 11 | Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006728. | 3.0 | 26 |
| 12 | Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 3.2 | 68 |
| 13 | Mutations in <i>pepQ</i> Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4590-4599. | 3.2 | 165 |
| 14 | Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 270-277. | 3.2 | 98 |
| 15 | Evaluation of Moxifloxacin-Containing Regimens in Pathologically Distinct Murine Tuberculosis Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4026-4030. | 3.2 | 38 |
| 16 | Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 869-874. | 7.1 | 116 |
| 17 | Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003823. | 3.0 | 25 |
| 18 | Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice. <i>Mycobacterial Diseases: Tuberculosis & Leprosy</i> , 2014, 04, 145. | 0.1 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Accelerated Detection of Mycolactone Production and Response to Antibiotic Treatment in a Mouse Model of <i>Mycobacterium ulcerans</i> Disease. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2618. | 3.0 | 38 |
| 20 | Assessment of Clofazimine Activity in a Second-Line Regimen for Tuberculosis in Mice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 608-612. | 5.6 | 114 |
| 21 | Bactericidal Activity Does Not Predict Sterilizing Activity: The Case of Rifapentine in the Murine Model of <i>Mycobacterium ulcerans</i> Disease. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2085. | 3.0 | 17 |
| 22 | Rapid, Serial, Non-invasive Assessment of Drug Efficacy in Mice with Autoluminescent <i>Mycobacterium ulcerans</i> Infection. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2598. | 3.0 | 28 |
| 23 | Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 15001-15005. | 7.1 | 33 |
| 24 | Autoluminescent <i>Mycobacterium tuberculosis</i> for Rapid, Real-Time, Non-Invasive Assessment of Drug and Vaccine Efficacy. <i>PLoS ONE</i> , 2012, 7, e29774. | 2.5 | 71 |
| 25 | Short-Course Chemotherapy with TMC207 and Rifapentine in a Murine Model of Latent Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 732-737. | 5.6 | 58 |
| 26 | Treatment of Tuberculosis with Rifamycin-containing Regimens in Immune-deficient Mice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1254-1261. | 5.6 | 54 |
| 27 | Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5485-5492. | 3.2 | 181 |
| 28 | Using Bioluminescence To Monitor Treatment Response in Real Time in Mice with <i>Mycobacterium ulcerans</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 56-61. | 3.2 | 28 |
| 29 | Failure Of Daily Treatment For Tuberculosis (TB) With Rifampin (R), Isoniazid (H) And Pyrazinamide (Z) In Immune-deficient Mice. , 2010, , . | | 1 |